Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)-Reference-Cited by-同舟云学术

Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)

Published:2019-04 Issue:5 Volume:48 Page:927-932
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Scherlinger Marc^ORCID,Langlois Emmanuel,Germain Vincent,Schaeverbeke Thierry

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference28 articles.

1. Biosimilars for the management of rheumatoid arthritis: economic considerations;Gulácsi;Expert Rev Clin Immunol,2015

2. The changing landscape of biosimilars in rheumatology;Dörner;Ann Rheum Dis,2016

3. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK;Aladul;BioDrugs Clin Immunother Biopharm Gene Ther,2017

4. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4;Emery;Ann Rheum Dis,2017

5. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases;Kay;Ann Rheum Dis,2018

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choice intention for the national volume-based procurement drug and its associated factors: a cross-sectional study on patients with late-life depression in China;BMC Psychiatry;2024-08-27

2. Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review;BioDrugs;2024-06-15

3. Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies;Reumatismo;2023-12-19

4. Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-11-23

5. Patients’ Perceptions of Biosimilars: A Systematic Review;BioDrugs;2023-09-07